Catenaa, Tuesday, February 17, 2026- Masimo stock surged by nearly 35% on Tuesday after the pulse oximeter maker announced that it will be acquired by Danaher in a $9.9 billion deal.
The companies said on Tuesday that Danaher will buy Masimo, which has been in a long legal battle with iPhone maker Apple over patents, for $180 per share. The offer represents a premium of 38.3% to Masimo’s last close.
The Transaction has been unanimously approved by both Masimo’s and Danaher’s Boards of Directors. Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment, operating autonomously while strengthening Danaher’s offering in acute care settings.
Contract research firms have been grappling with uncertainty around drug pricing regulations in the U.S., potential tariff policies and softer academic and government research funding.
Masimo has a market capitalization of about $7 billion, while Danaher is valued at over $150 billion, according to Reuters calculations.
Katie Szyman, Chief Executive Officer of Masimo, stated: “We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring. Danaher shares our commitment to investing in talent and innovation and will be an ideal fit to help power the next chapter of Masimo.”
Michelle Brennan, Chairman of Masimo’s Board of Directors, said that this transaction represents a unique opportunity to deliver certain and premium value for Masimo’s shareholders, enhance outcomes for customers and patients, and provide compelling career growth paths for our employees across the world.
The Transaction is subject to the satisfaction or waiver of certain closing conditions, including the receipt of required regulatory approvals. It is expected to close in the second half of 2026.
Masimo will report its fourth quarter and full-year 2025 results on February 26. Due to the Transaction, Masimo will not be hosting an earnings conference call.
